Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Restoration in HCV GT1a with Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + Ribavirin
NCT02476617Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2015
- Primary completion
- Aug 2016
- Modality
- Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 3, open-label, single-arm trial of ombitasvir, paritaprevir, ritonavir and dasabuvir in hepatitis C virus infection, sponsored by AbbVie Inc. Primary endpoint: Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12. Started Jun 2015; status: completed.
02
Drugs
ombitasvirparitaprevirritonavirdasabuvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT02476617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02476617.